Chronic lymphocytic leukaemia: Current management

被引：3

作者：

Aurran-Schleinitz, T. ^{[1
]}

Arnoulet, C. ^{[2
]}

Ivanov, V. ^{[1
]}

Coso, D. ^{[1
]}

Rey, J. ^{[1
]}

Schiano, J. -M. ^{[1
]}

Stoppa, A. -M. ^{[1
]}

Bouabdallah, R. ^{[1
]}

Gastaut, J. -A. ^{[1
]}

机构：

[1] Inst J Paoli I Calmettes, Dept Oncohematol, F-13273 Marseille 9, France

[2] Inst J Paoli I Calmettes, Lab Biopathol, F-13273 Marseille 9, France

来源：

REVUE DE MEDECINE INTERNE | 2008年 / 29卷 / 05期

关键词：

chronic lymphocytic leukemia; prognostic factors; fludarabine; rituximab; alemtuzumab;

D O I：

10.1016/j.revmed.2007.10.414

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction. - Chronic lymphocytic leukemia (CLL) is the most common leukaemia in the Western world. Recent advancement in the aetiology, pathophysiology and the development of new therapeutics tools have significantly modified the current management of CLL. Current knowledge and key points. - The cellular origin of CLL is still unknown. The current main hypothesis will be first briefly described. This review will then focus on the newly defined prognostic factors and the development and use of new drugs for the treatment of CLL. To describe the modem and practical management of CLL, we will compare classical and new prognostic markers. Then, we will discuss the various therapeutic options including chemotherapy and immunotherapy (monoclonal antibodies, allogenic transplantation), and define their current respective indications. Future prospects and projects. - These new diagnostic and prognostic markers will allow the characterization of new prognostic subgroups of patients. This will lead to a targeted and individualized therapeutic approach. We will present the first results of clinical trials and the on-going studies conducted in this disease. (C) 2008 Public par Elsevier Masson SAS.

引用

页码：424 / 435

页数：12

共 84 条

[1] Identification of a new monoclonal B-cell subset in unaffected first-degree relatives in familial chronic lymphocytic leukemia [J].

Aurran-Schleinitz, T ;

Telford, W ;

Perfetto, S ;

Caporaso, N ;

Wilson, W ;

Stetler-Stevenson, MA ;

Zenger, VE ;

Abbasi, F ;

Marti, GE .

LEUKEMIA, 2005, 19 (12) :2339-2341

[2] Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia [J].

Binet, JL ;

Caligaris-Cappio, F ;

Catovsky, D ;

Cheson, B ;

Davis, T ;

Dighiero, G ;

Döhner, H ;

Hallek, M ;

Hillmen, P ;

Keating, M ;

Montserrat, E ;

Kipps, TJ ;

Rai, K .

BLOOD, 2006, 107 (03) :859-861

[3]

BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO

[4]

2-V

[5]

Brugiatelli M, 2006, HAEMATOLOGICA, V91, P1662

[6] Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 [J].

Byrd, JC ;

Rai, K ;

Peterson, BL ;

Appelbaum, FR ;

Morrison, VA ;

Kolitz, JE ;

Shepherd, L ;

Hines, JD ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2005, 105 (01) :49-53

[7] Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity [J].

Byrd, JC ;

Murphy, T ;

Howard, RS ;

Lucas, MS ;

Goodrich, A ;

Park, K ;

Pearson, M ;

Waselenko, JK ;

Ling, G ;

Grever, MR ;

Grillo-Lopez, AJ ;

Rosenberg, J ;

Kunkel, L ;

Flinn, IW .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2153-2164

[8] The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction [J].

Byrd, JC ;

Kitada, S ;

Flinn, IW ;

Aron, JL ;

Pearson, M ;

Lucas, N ;

Reed, JC .

BLOOD, 2002, 99 (03) :1038-1043

[9] A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia [J].

Calin, GA ;

Ferracin, M ;

Cimmino, A ;

Di Leva, G ;

Shimizu, M ;

Wojcik, SE ;

Iorio, MV ;

Visone, R ;

Sever, NI ;

Fabbri, M ;

Iuliano, R ;

Palumbo, T ;

Pichiorri, F ;

Roldo, C ;

Garzon, R ;

Sevignani, C ;

Rassenti, L ;

Alder, H ;

Volinia, S ;

Liu, CG ;

Kipps, TJ ;

Negrini, M ;

Croce, CM .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (17) :1793-1801

[10] Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial [J].

Catovsky, D. ;

Richards, S. ;

Matutes, E. ;

Oscier, D. ;

Dyer, M. J. S. ;

FBezares, R. ;

Pettitt, A. R. ;

Hamblin, T. ;

Milligan, D. W. ;

Child, J. A. ;

Hamilton, M. S. ;

Dearden, C. E. ;

Smith, A. G. ;

Bosanquet, A. G. ;

Davis, Z. ;

Brito-Babapulle, V. ;

Else, M. ;

Wade, R. ;

Hillmen, P. .

LANCET, 2007, 370 (9583) :230-239

← 1 2 3 4 5 6 7 8 9 →